Kos, Barr Settle Niaspan Patent Litigation With Unusual Deal

Law360, New York (April 13, 2005, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. and Kos Pharmaceuticals Inc. have penned an unusual settlement agreement to put an end to their patent litigation over Kos' cholesterol lowering drugs Niaspan and Advicor, the two companies said Wednesday.

Under the seven-year deal, Barr subsidiary Duramed Pharmaceuticals will co-promote Niaspan and Advicor -- as well as any future dosages or modified versions -- to obstetricians, gynecologists and other women's healthcare practitioners in exchange for royalties on quarterly and yearly sales.

Kos will help train a Duramed sales force of 40 to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.